Quantcast

Latest Astellas Pharma US Inc. Stories

2011-05-19 12:00:00

DEERFIELD, Ill., May 19, 2011 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas") recently hired Mark Reisenauer as vice president of sales and marketing, oncology. Reporting directly to Patrick Shea, senior vice president of marketing & sales, Reisenauer will be responsible for all U.S. commercial activities supporting marketed products, the company's oncology co-promotion partners and will lead commercial planning for early stage development compounds. "Astellas has made...

2011-05-17 14:31:00

DEERFIELD, Ill., May 17, 2011 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas Pharma US"), U.S. subsidiary of Astellas Pharma Inc. (Tokyo: TSE: 4503, "the Company"), today announced the results of a pivotal phase III clinical trial for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder (OAB), which show mirabegron significantly improves key OAB symptoms - urinary incontinence (leakage of urine) and frequency of micturition...

2011-04-11 08:09:00

STAINES, England, April 11, 2011 /PRNewswire/ -- Astellas Pharma Europe Ltd. (APEL), the European subsidiary of Tokyo-based Astellas Pharma Inc., one of the world's top 20 pharmaceutical companies, today announced the appointment of Ken Jones as its President and CEO. Mr Jones, who since July 2007 has held the position of COO at Astellas Pharma Europe Ltd., succeeds Mr Masao Yoshida, who has been appointed as President and CEO of Astellas Pharma US, Inc., the U.S. subsidiary of...

2011-03-22 09:36:00

TOKYO, March 22, 2011 /PRNewswire-FirstCall/ -- Astellas Pharma Inc.(TSE:4503,"Astellas") ( http://www.astellas.com/en/corporate/) today announced the results of two pivotal phase III clinical trials for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder (OAB), show mirabegron significantly improves key OAB symptoms - urinary incontinence and frequency of micturition[1,2]. These data were presented for the first time this week at...

2010-11-02 08:00:00

TOKYO, Nov. 2, 2010 /PRNewswire/ -- Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced that Donald B. Rice, PhD. will retire from Astellas Pharma Inc.'s affiliate Agensys, Inc. ("Agensys"). Sef Kurstjens, M.D., PhD. has been appointed the new Chief Executive Officer and President. Dr. Rice founded Agensys, Inc. (formerly UroGenesys, Inc.) in 1996. The company, located in Santa Monica, CA, USA, was acquired by Astellas in December,...

2010-11-02 07:00:00

CHICAGO and DEERFIELD, Ill., Nov. 2, 2010 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a research-based pharmaceutical company based in Deerfield, Ill., is pleased to donate 150 used laptops to Midtown Educational Foundation, a nonprofit academic enrichment organization that serves over 1,000 students and parents in need each year through its Chicago-based Metro Achievement Center for girls and Midtown Center for boys. "The Midtown Educational Foundation is thrilled to partner...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related